期刊文献+

替吉奥胶囊姑息治疗晚期恶性肿瘤的临床研究 被引量:8

Clinical Study of TS-1 in Palliative Treatment of Advanced Cancer
下载PDF
导出
摘要 目的探讨替吉奥胶囊姑息治疗晚期恶性肿瘤的疗效及不良反应。方法收集2009年10月至2011年5月晚期恶性肿瘤51例,均采用单药替吉奥(TS-1),40mg/(m2·d),2次/日,连续口服四周,休息2周为一周期,每例患者至少接受治疗2个周期,治疗结束后进行评价有效率、生存率及不良反应。结果 51例患者均顺利完成化疗。总有效率(CR+PR)为29.4%。生活质量改善增加率(KPS大于80分)31.4%。随访6到12个月,采用Kaplan-Meier分析显示1年累积生存率为37.3%,无严重不良反应。结论替吉奥是姑息治疗晚期恶性肿瘤是一种安全而有效的方法。 To investigate the clinical values and adverse reactions of TS-1 in palliative treatment of advanced cancer. Methods From October 2009 to May 2011,51 cases of advanced cancer treated by twice daily of TS-1 40mg / (m^2·d) ,bid,from day 1 to day 28,rest for 2 week,and repeated every six weeks. Each patient received at least two cycles. The effect,survival and adverse reactions were evaluated. Results 51 patients were successfully completed chemotherapy. The total effective rate ( CR + PR) was 29. 4% . The improvement rate of the quality of life ( KPS more than 80 points) was 31. 4% . Follow-up for 6 to 12 months,the Ka-plan-Meier analysis showed that 1-year cumulative survival rate was 37. 3% ,with no serious adverse reactions. Conclusion TS-1 is a safe and effective method in palliative treatment of advanced cancer.
出处 《中国老年保健医学》 2013年第3期53-55,共3页 Chinese Journal of Geriatric Care
关键词 替吉奥胶囊 晚期恶性肿瘤 姑息化学治疗 TS-1 advanced cancer palliative chemotherapy
  • 相关文献

参考文献11

  • 1周际昌.实用肿瘤内科学[M].第二版.北京:人民卫生出版社,2006:45-47.
  • 2Alberts SR, Cervantes A, VANDE Velde C J, et al. Gastric cancer : epi- demiology, pathology and treatment [ J] .Ann Oncol, 2003, 14 (suppl) :$31.
  • 3Malet-Martino M, Martino R. Clinical studies of three oral pradrugs of 5-fluorouraeil ( eapecitabine, UFr, S-I ) : a review [ J ]. Oneologist, 2002, 7(4) :288 -323.
  • 4苗淑荣,任磊.奥沙利铂联合替吉奥治疗晚期及复发性胃癌疗效观察[J].中国现代药物应用,2010,4(11):134-134. 被引量:10
  • 5何忠杰,江荣科,朱丹丹,刘磊.奥沙利铂联合替吉奥胶囊治疗晚期胃癌的临床观察[J].实用癌症杂志,2010,25(3):286-288. 被引量:74
  • 6Wasaburo K, Hiroyuki N, TaKuo H, et al. GotohM : SI plus cisplatin ver- sus SI alone for first-line treatment of advanced gastric cancer( SPIR- ITS trial) : a phase BI trial [ J ]. Lancet Oncol, 2008,9 ( 3 ) : 215 - 221.
  • 7Nagashima F. Ohtsu A. yoshida S, et al. Janpanese nation wide post- marketing survey of S-1 in patients with advanced gastric cancer [ J ]. Gastric Cancer,2005,8 ( 1 ) :6 - 11.
  • 8Maehara Y. S-1 in gastric cancer: A comprehensive review[ J]. Gastric Cancer,2003,6( Suppl 1 ) :2 - 8.
  • 9白坂哲彦,佃守,犬山征夫他.新规经口抗癌剂码-1(S.I).癌匕化学疗法,2001:28(6):855-864(日文).
  • 10Ohtsu A,Baba H, Sakata Y, et al Phase II study of S-I, a novel oral fluoro-Dhy, imidine derivative, in patients with metastatic colorectal carcinotrm [ J ]. Br J Cancer. 2000:83 ( 2 ) : 141 - 145.

二级参考文献14

共引文献81

同被引文献37

引证文献8

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部